The lung microbiome in end-stage Lymphangioleiomyomatosis

Respir Res. 2021 Oct 26;22(1):277. doi: 10.1186/s12931-021-01873-y.


Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome signature compared to patients with end-stage chronic obstructive pulmonary disease.

Keywords: Lymphangioleiomyomatosis; Microbiome.

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Disease Progression
  • Dysbiosis
  • Humans
  • Lung / microbiology*
  • Lung Diseases, Fungal / diagnosis
  • Lung Diseases, Fungal / microbiology
  • Lymphangioleiomyomatosis / diagnosis
  • Lymphangioleiomyomatosis / microbiology*
  • Microbiota*
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / microbiology*
  • Respiratory Tract Infections / diagnosis
  • Respiratory Tract Infections / microbiology*
  • Ribotyping